Everything you need to succeed Endtoend medical care, built around you
Top Benefits: Enhances weight loss beyond GLP-1 alone Improves insulin response and glucose stability Boosts overall metabolic performance Once-weekly injectable therapy that mimics the natural GLP-1 hormone to improve appetite control and metabolic efficiency
Tirzepatide, with its leading position and clear efficacy, has become the current standard treatment
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Behavioral choice treatment promotes continuing weight loss: preliminary results of a cognitive-behavioral decision-based treatment for obesity
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two hormones that are involved in maintaining healthy blood sugar levels and sending signals from the gut to the brain when people are full
